The success of Viagra initially sparked a surge for pharma, but recent shifts present a complicated picture for shareholders. Lower-cost versions are eating into revenue, and ongoing legal battles add additional risk https://deannabbyx127879.blogacep.com/46804022/sildenafil-and-big-pharma-a-risky-investment